Monica Reckner

449 total citations
8 papers, 75 citations indexed

About

Monica Reckner is a scholar working on Oncology, Genetics and Infectious Diseases. According to data from OpenAlex, Monica Reckner has authored 8 papers receiving a total of 75 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Oncology, 4 papers in Genetics and 2 papers in Infectious Diseases. Recurrent topics in Monica Reckner's work include Virus-based gene therapy research (4 papers), Viral gastroenteritis research and epidemiology (2 papers) and Cancer-related Molecular Pathways (2 papers). Monica Reckner is often cited by papers focused on Virus-based gene therapy research (4 papers), Viral gastroenteritis research and epidemiology (2 papers) and Cancer-related Molecular Pathways (2 papers). Monica Reckner collaborates with scholars based in United States, France and Netherlands. Monica Reckner's co-authors include Gwen Nichols, Jianguo Zhi, Lillian L. Siu, Jourik A. Gietema, Wilson H. Miller, Brian Higgins, Antoîne Italiano, Jean‐Yves Blay, Hal W. Hirte and Steven Blotner and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Annals of Oncology.

In The Last Decade

Monica Reckner

8 papers receiving 74 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Monica Reckner United States 4 54 42 18 10 10 8 75
Arman Öner Germany 2 42 0.8× 49 1.2× 10 0.6× 6 0.6× 5 0.5× 2 144
Anahita Rafiei Switzerland 5 38 0.7× 38 0.9× 15 0.8× 6 0.6× 49 4.9× 8 122
Linda J. van Weele Netherlands 3 37 0.7× 77 1.8× 9 0.5× 13 1.3× 7 0.7× 4 157
Mariko H. Foecke United States 3 18 0.3× 66 1.6× 8 0.4× 4 0.4× 8 0.8× 6 117
Adam J. Widman United States 7 43 0.8× 21 0.5× 20 1.1× 9 0.9× 8 0.8× 12 116
Alexanda K. Ling Canada 5 41 0.8× 141 3.4× 9 0.5× 4 0.4× 3 0.3× 5 160
Andrew W. Navia United States 5 39 0.7× 51 1.2× 6 0.3× 19 1.9× 3 0.3× 6 197
Dan McDonald United States 9 90 1.7× 37 0.9× 15 0.8× 22 2.2× 3 0.3× 12 136
Reyes Acosta United States 2 20 0.4× 71 1.7× 21 1.2× 6 0.6× 6 0.6× 4 107
Susmita Samanta United States 3 27 0.5× 50 1.2× 12 0.7× 4 0.4× 8 0.8× 6 85

Countries citing papers authored by Monica Reckner

Since Specialization
Citations

This map shows the geographic impact of Monica Reckner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Monica Reckner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Monica Reckner more than expected).

Fields of papers citing papers by Monica Reckner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Monica Reckner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Monica Reckner. The network helps show where Monica Reckner may publish in the future.

Co-authorship network of co-authors of Monica Reckner

This figure shows the co-authorship network connecting the top 25 collaborators of Monica Reckner. A scholar is included among the top collaborators of Monica Reckner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Monica Reckner. Monica Reckner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Naik, Shruthi, Bradley C. Leibovich, Tanner Miest, et al.. (2022). Safety and efficacy of neoadjuvant intravesical oncolytic MV-NIS in patients with urothelial carcinoma.. Journal of Clinical Oncology. 40(6_suppl). 509–509. 7 indexed citations
2.
3.
Merchan, Jaime R., Manish R. Patel, Timothy P. Cripe, et al.. (2020). Relationship of infusion duration to safety, efficacy, and pharmacodynamics (PD): Second part of a phase I-II study using VSV-IFNβ-NIS (VV1) oncolytic virus in patients with refractory solid tumors.. Journal of Clinical Oncology. 38(15_suppl). 3090–3090. 12 indexed citations
4.
Sznol, Mario, Jose Lutzky, Alex A. Adjei, et al.. (2020). Phase II trial of Voyager-V1 (vesicular stomatitis virus expressing human IFNβ and NIS, VV1), in combination with cemiplimab (C) in patients with NSCLC, melanoma, HCC or endometrial carcinoma.. Journal of Clinical Oncology. 38(15_suppl). TPS3161–TPS3161. 1 indexed citations
5.
Leibovich, Bradley C., Tanner Miest, Paul R. Young, et al.. (2020). Safety and efficacy of neoadjuvant intravesical oncolytic MV-NIS in patients undergoing radical cystectomy (RC) for urothelial carcinoma but ineligible for neoadjuvant cisplatin-based chemotherapy.. Journal of Clinical Oncology. 38(15_suppl). TPS3172–TPS3172. 1 indexed citations
6.
7.
Siu, Lillian L., Antoîne Italiano, Wilson H. Miller, et al.. (2014). Phase 1 dose escalation, food effect, and biomarker study of RG7388, a more potent second-generation MDM2 antagonist, in patients (pts) with solid tumors.. Journal of Clinical Oncology. 32(15_suppl). 2535–2535. 45 indexed citations
8.
Nichols, Gwen, Monica Reckner, Lyubomir T. Vassilev, et al.. (2011). Pharmacokinetics (PK) and pharmacodynamics (PD) of RG7112, an oral murine double minute 2 (MDM2) antagonist, in patients with leukemias and solid tumors.. Journal of Clinical Oncology. 29(15_suppl). 3039–3039. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Arman Öner Breakdown of academic impact, for papers by Anahita Rafiei Breakdown of academic impact, for papers by Linda J. van Weele Breakdown of academic impact, for papers by Mariko H. Foecke Breakdown of academic impact, for papers by Adam J. Widman Breakdown of academic impact, for papers by Alexanda K. Ling Breakdown of academic impact, for papers by Andrew W. Navia Breakdown of academic impact, for papers by Dan McDonald Breakdown of academic impact, for papers by Reyes Acosta Breakdown of academic impact, for papers by Susmita Samanta
Rankless by CCL
2026